X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
index medicus (50) 50
humans (45) 45
hematology (43) 43
male (39) 39
female (38) 38
middle aged (37) 37
oncology (28) 28
adult (27) 27
aged (26) 26
adolescent (24) 24
leukemia (20) 20
transplantation (20) 20
acute myeloid leukemia (18) 18
cancer (16) 16
young adult (16) 16
retrospective studies (14) 14
stem cells (14) 14
aged, 80 and over (13) 13
analysis (13) 13
bone-marrow-transplantation (13) 13
prognosis (13) 13
survival rate (13) 13
chemistry (12) 12
hematology, oncology and palliative medicine (12) 12
hematopoietic stem cells (12) 12
leukemia, myeloid, acute - mortality (12) 12
metallurgy (11) 11
treatment outcome (11) 11
adults (10) 10
hematopoietic stem cell transplantation (10) 10
leukemia, myeloid, acute - drug therapy (10) 10
leukemia, myeloid, acute - therapy (10) 10
medicine & public health (10) 10
stem-cell transplantation (10) 10
survival (10) 10
leukemia, myeloid, acute - genetics (9) 9
patients (9) 9
relapse (9) 9
remission (9) 9
transplantation, homologous (9) 9
acute myeloid-leukemia (8) 8
chemotherapy (8) 8
electricity (8) 8
human necessities (8) 8
hygiene (8) 8
immunology (8) 8
medical or veterinary science (8) 8
myeloid leukemia (8) 8
preparations for medical, dental, or toilet purposes (8) 8
therapy (8) 8
basic electric elements (7) 7
disease-free survival (7) 7
medical prognosis (7) 7
outcomes (7) 7
physics (7) 7
research (7) 7
risk factors (7) 7
specific use of cosmetics or similar toiletpreparations (7) 7
acute myelogenous leukemia (6) 6
cord blood transplantation (6) 6
genetic aspects (6) 6
impact (6) 6
mutation (6) 6
oncology, experimental (6) 6
organic chemistry (6) 6
patient outcomes (6) 6
performing operations (6) 6
recurrence (6) 6
transporting (6) 6
versus-host-disease (6) 6
age factors (5) 5
allogeneic hematopoietic stem cell transplantation (5) 5
aml (5) 5
bone marrow (5) 5
cells (5) 5
cytarabine (5) 5
cytogenetics (5) 5
diseases (5) 5
dose-response relationship, drug (5) 5
follow-up studies (5) 5
graft-versus-host disease (5) 5
management (5) 5
medical colleges (5) 5
myelodysplastic syndrome (5) 5
original (5) 5
original article (5) 5
precursor cell lymphoblastic leukemia-lymphoma - mortality (5) 5
risk (5) 5
survival analysis (5) 5
trial (5) 5
unrelated donors (5) 5
acute lymphoblastic-leukemia (4) 4
adhesives (4) 4
allogeneic hematopoietic cell transplantation (4) 4
allografts (4) 4
antennas, i.e. radio aerials (4) 4
antineoplastic agents - adverse effects (4) 4
antineoplastic combined chemotherapy protocols - therapeutic use (4) 4
blood (4) 4
child (4) 4
more...
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Nature Genetics, ISSN 1061-4036, 05/2016, Volume 48, Issue 5, pp. 569 - 574
Journal Article
Cancer Science, ISSN 1347-9032, 11/2015, Volume 106, Issue 11, pp. 1590 - 1595
This phase I trial conducted in Japanese patients with acute myeloid leukemia evaluated the safety, maximum tolerated dose and pharmacokinetics of volasertib... 
maximum tolerated dose | Polo‐like kinase 1 | Acute myeloid leukemia | Japanese | clinical trial phase I | Maximum tolerated dose | Polo-like kinase 1 | Clinical trial phase I | DIAGNOSIS | CELLS | MANAGEMENT | CANCER | THERAPY | ONCOLOGY | PRECLINICAL MODELS | RECOMMENDATIONS | BI 6727 | TARGETS | OUTCOMES | Protein Kinase Inhibitors - pharmacokinetics | Proto-Oncogene Proteins - antagonists & inhibitors | Humans | Japan | Middle Aged | Pteridines - adverse effects | Male | Pteridines - pharmacokinetics | Pteridines - administration & dosage | Antineoplastic Agents - administration & dosage | Protein Kinase Inhibitors - adverse effects | Cell Cycle Proteins - antagonists & inhibitors | Dose-Response Relationship, Drug | Protein Kinase Inhibitors - administration & dosage | Asian Continental Ancestry Group | Maximum Tolerated Dose | Antineoplastic Agents - adverse effects | Protein-Serine-Threonine Kinases - antagonists & inhibitors | Aged, 80 and over | Leukemia, Myeloid, Acute - drug therapy | Female | Aged | Antineoplastic Agents - pharmacokinetics | Appetite | Participation | Research funding | Toxicity | Myeloid leukemia | Leukemia | Clinical trials | Nausea | Patients | Stomatitis | Chemotherapy | Consent | Cell cycle | Hypokalemia | Sepsis | Remission | Pharmacokinetics | Neutropenia | Apoptosis | Original
Journal Article
Blood, ISSN 0006-4971, 11/2019, Volume 134, Issue Supplement_1, pp. 5690 - 5690
Background: Extramedullary (EM) relapses were sometimes observed in acute leukemia patients both after chemotherapy and allo-SCT. Our recent study described... 
Journal Article
Cancer Immunology, Immunotherapy, ISSN 0340-7004, 07/2017, Volume 66, Issue 7, pp. 851 - 863
Wilms' tumor 1 (WT1) is a promising target of new immunotherapies for acute myeloid leukemia (AML) as well as for other cancers. OCV-501 is a helper peptide... 
Helper peptide | OCV-501 | Cancer vaccine | WT1 | Acute myeloid leukemia | Immunotherapy | CD4(+) T-CELLS | INDUCTION | IMMUNOLOGY | CANCER | TUMOR-ANTIGEN | RESPONSES | MELANOMA | ONCOLOGY | EPITOPE LONG PEPTIDE | LYMPHOCYTES | HLA-A2 Antigen - genetics | Cancer Vaccines - pharmacology | Humans | Middle Aged | Male | Th1 Cells - immunology | Dose-Response Relationship, Drug | T-Lymphocytes, Cytotoxic - drug effects | WT1 Proteins - pharmacology | WT1 Proteins - immunology | Aged, 80 and over | Female | Leukemia, Myeloid, Acute - therapy | T-Lymphocytes, Cytotoxic - immunology | Th1 Cells - drug effects | WT1 Proteins - administration & dosage | Cancer Vaccines - administration & dosage | Vaccines, Subunit - immunology | HLA-DR beta-Chains - genetics | Remission Induction | Cancer Vaccines - immunology | Maximum Tolerated Dose | Vaccines, Subunit - pharmacology | Lymphocyte Activation - drug effects | Vaccines, Subunit - administration & dosage | Cell Line, Tumor | Aged | Cohort Studies | Peptides | Oncology, Experimental | Clinical trials | Research | Vaccines | T cells | Cancer | Cytolytic activity | Hypersensitivity (delayed) | Myeloid leukemia | Leukemia | Hypersensitivity | Cytotoxicity | Leukocytes (mononuclear) | Pharmacology | Lymphocytes T | In vitro testing | Blast | Wilms' tumor | Patients | WT1 protein | Immunology | Lymphocytes B | Lymphocytes | Peripheral blood mononuclear cells | Remission | Histocompatibility antigen HLA | Blast cells | Original
Journal Article
Cancer Science, ISSN 1347-9032, 10/2018, Volume 109, Issue 10, pp. 3235 - 3244
Gilteritinib, a novel, highly specific, potent fms‐like tyrosine kinase 3/AXL inhibitor, demonstrated antileukemic activity in patients with... 
fms‐like tyrosine kinase 3 | mutation | hematopoiesis | acute myeloid leukemia | bone marrow | fms-like tyrosine kinase 3 | INTERNAL TANDEM DUPLICATION | TYROSINE KINASE AXL | CONTROLLED-TRIAL | MULTICENTER | ACTIVATION | FLT3 INHIBITOR | SORAFENIB | ONCOLOGY | THERAPEUTIC TARGET | MUTATIONS | QUIZARTINIB | Thrombocytopenia - epidemiology | fms-Like Tyrosine Kinase 3 - antagonists & inhibitors | Japan - epidemiology | Humans | Middle Aged | Neoplasm Recurrence, Local - drug therapy | Drug Resistance, Neoplasm | Male | Pyrazines - therapeutic use | Dose-Response Relationship, Drug | Neoplasm Recurrence, Local - pathology | Aged, 80 and over | Leukemia, Myeloid, Acute - drug therapy | Receptor Protein-Tyrosine Kinases - antagonists & inhibitors | Female | Neoplasm Recurrence, Local - blood | Protein Kinase Inhibitors - pharmacokinetics | Proto-Oncogene Proteins - antagonists & inhibitors | Creatine Kinase - blood | Drug Administration Schedule | Leukemia, Myeloid, Acute - pathology | Treatment Outcome | Leukemia, Myeloid, Acute - blood | Thrombocytopenia - chemically induced | Aniline Compounds - pharmacokinetics | Maximum Tolerated Dose | Protein Kinase Inhibitors - therapeutic use | Pyrazines - pharmacokinetics | Aged | Aniline Compounds - therapeutic use | Tyrosine | Research | Creatine | Creatine kinase | Oncology, Experimental | Cancer | Leukemia | Kinases | Blood | Axl protein | Syncope | Consent | Remission | Protein-tyrosine kinase | Deoxyribonucleic acid--DNA | Thrombocytopenia | Research funding | Myeloid leukemia | Patients | L-Lactate dehydrogenase | Studies | Medical prognosis | Lysis | Response rates | Lactic acid | Mutation | Pharmacokinetics | Platelets | Acute myeloid leukemia | Index Medicus | Original
Journal Article
Journal of the Acoustical Society of America, ISSN 0001-4966, 10/2016, Volume 140, Issue 4, pp. 3174 - 3174
The importance of wave-based room acoustics simulation has been increasing in various fields of researches and design-stages. The problem remained, however, is... 
Journal Article
Blood, ISSN 0006-4971, 11/2018, Volume 132, Issue Supplement 1, pp. 438 - 438
Abstract Background: Recent advance in genetic analysis has revealed that many mutations are associated with the development, progression and/or prognosis of... 
Journal Article
Blood, ISSN 0006-4971, 11/2018, Volume 132, Issue Supplement 1, pp. 2820 - 2820
Abstract Background:Although cytogenetic abnormalities at diagnosis are recognized as one of the most potent prognostic factors in acute leukemia patients, CCH... 
Journal Article
Journal Article
Leukemia, ISSN 0887-6924, 02/2019, Volume 33, Issue 2, pp. 358 - 370
Journal Article
Annals of Hematology, ISSN 0939-5555, 9/2019, Volume 98, Issue 9, pp. 2179 - 2186
The prognosis of patients with acute myeloid leukemia (AML) is dismal after experiencing multiple relapses. This study retrospectively analyzed outcomes of... 
Medicine & Public Health | Hematology | Multiple relapses | Allogeneic hematopoietic cell transplantation | Relapsed | Oncology | Acute myeloid leukemia | AML | MANAGEMENT | ACUTE MYELOGENOUS LEUKEMIA | ADULTS | SCRIPTS | OUTCOMES | HEMATOLOGY | MINIMAL RESIDUAL DISEASE | TRUMP DATA
Journal Article
American Journal of Hematology, ISSN 0361-8609, 05/2016, Volume 91, Issue 5, pp. E284 - E292
Older recipient and donor age were associated with higher incidences of severe graft‐versus‐host disease (GVHD) and mortality after allogeneic hematopoietic... 
JAPAN SOCIETY | REDUCED-INTENSITY | ADULT PATIENTS | ACUTE LYMPHOBLASTIC-LEUKEMIA | INTERNATIONAL BLOOD | ACUTE MYELOID-LEUKEMIA | DONOR TRANSPLANTATION | COMPARABLE SURVIVAL | HEMATOLOGY | VERSUS-HOST-DISEASE | HEMATOLOGIC MALIGNANCIES | Japan - epidemiology | Recurrence | Graft vs Host Disease - epidemiology | Peripheral Blood Stem Cell Transplantation - adverse effects | Age Factors | Humans | Middle Aged | Cord Blood Stem Cell Transplantation - statistics & numerical data | Male | Precursor Cell Lymphoblastic Leukemia-Lymphoma - mortality | Living Donors | HLA Antigens - genetics | Cause of Death | Bone Marrow Transplantation - statistics & numerical data | Incidence | Cord Blood Stem Cell Transplantation - adverse effects | Myelodysplastic Syndromes - therapy | Precursor Cell Lymphoblastic Leukemia-Lymphoma - therapy | ABO Blood-Group System - genetics | Female | Graft vs Host Disease - etiology | Leukemia, Myeloid, Acute - therapy | Siblings | Severity of Illness Index | Blood Platelets | Neutrophils | Proportional Hazards Models | Peripheral Blood Stem Cell Transplantation - mortality | Graft Survival | Treatment Outcome | Peripheral Blood Stem Cell Transplantation - statistics & numerical data | Leukemia, Myeloid, Acute - mortality | Bone Marrow Transplantation - mortality | Myelodysplastic Syndromes - mortality | Bone Marrow Transplantation - adverse effects | Aged | Cord Blood Stem Cell Transplantation - mortality | Histocompatibility | Mortality | Leukemia | Patient outcomes | Stem cells | Bone marrow | Transplantation | Comparative analysis | Hematopoietic stem cells
Journal Article